Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this case study, the researchers investigated a 44-year-old woman who developed rapidly progressing alopecia universalis after receiving a COVID-19 vaccine, and reviewed existing literature to explore potential links between COVID-19 vaccines and autoimmune hair loss conditions like alopecia areata and universalis.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

In this study, researchers observed that among pediatric alopecia areata patients at Dr. M. Djamil General Hospital Padang, patchy alopecia was most common, affecting 80% of cases, with frequent trichoscopic features including yellow dots, black dots, and broken hairs.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

In this case report, an 11-year-old girl with alopecia totalis initially treated with minoxidil experienced hypertrichosis, which reversed upon stopping the medication; hair regrowth on the scalp was achieved with tofacitinib after minoxidil discontinuation.

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.

In this case report, a nearly 12-year-old boy with alopecia universalis and atopic dermatitis experienced full hair regrowth and improved dermatitis following treatment with upadacitinib, a JAK 1 inhibitor, showing notable positive effects on his psychological well-being and family.

This study suggests that potent topical corticosteroid occlusion may be a safe and effective treatment option for pediatric patients with severe alopecia areata, although further research is needed on its long-term safety and recurrence.

In this case report, the authors describe a child and his mother with a heterozygous STING variant linked to SAVI, who exhibited atypical disease courses and varying organ involvement, underlining the diverse clinical manifestations of SAVI.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

In this study, conducted at a single hospital from 2017 to 2020, researchers analyzed epidemiological factors, clinical patterns, and associated comorbidities in patients with clinically diagnosed alopecia areata using questionnaires, clinical examinations, and lab data. Results are not reported in the abstract.

This review discusses the pathophysiology of alopecia areata, highlighting the role of CD8 cytotoxic T cells and the upregulation of JAK signaling pathways; it reports no new experimental results.

This study suggests that congenital alopecia areata should be considered for newborns with alopecia, supporting the use of topical corticosteroids as a reasonable initial treatment option based on observed regrowth.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

This review discusses genetic conditions linked to complete scalp alopecia in children, identifying six genetic causes, but reports no new clinical results.

In this study, 75% of alopecia areata patients showed improvement after treatment with 35% trichloroacetic acid, leading the researchers to conclude it is a safe and effective option for treating this condition.

This case study describes a 5-year-old boy with vitamin D dependent rickets type 2, motor delays, and alopecia totalis who showed improved biochemical parameters with calcium and calcitriol treatment.

This study reports that diphenylcyclopropenone topical immunotherapy resulted in any hair regrowth for 69% of patients with alopecia areata, but with common side effects including mild to severe contact dermatitis.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.

This report describes siblings with vitamin D-dependent rickets type 2, characterized by growth retardation, alopecia totalis, and low 25(OH)D3 levels, highlighting its autosomal recessive pattern and distinction from other rickets types.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This study describes a case where a patient with alopecia totalis treated with the JAK inhibitor tofacitinib showed hair regrowth but experienced worsened facial acne.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This article reviews alopecia areata as a chronic autoimmune disease affecting hair follicles and discusses its association with other autoimmune conditions, but provides no new clinical findings.